1
|
Tainta M, Ecay-Torres M, de Arriba M, Barandiaran M, Otaegui-Arrazola A, Iriondo A, Garcia-Sebastian M, Estanga A, Saldias J, Clerigue M, Gabilondo A, Ros N, Mugica J, Barandiaran A, Mangialasche F, Kivipelto M, Arrospide A, Mar J, Martinez-Lage P. GOIZ ZAINDU study: a FINGER-like multidomain lifestyle intervention feasibility randomized trial to prevent dementia in Southern Europe. Alzheimers Res Ther 2024; 16:44. [PMID: 38413990 PMCID: PMC10898038 DOI: 10.1186/s13195-024-01393-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Accepted: 01/16/2024] [Indexed: 02/29/2024]
Abstract
BACKGROUND GOIZ ZAINDU ("caring early" in Basque) is a pilot study to adapt the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) methodology to the Basque population and evaluate the feasibility and adherence to a FINGER-like multidomain intervention program. Additional aims included the assessment of efficacy on cognition and data collection to design a large efficacy trial. METHOD GOIZ ZAINDU is a 1-year, randomized, controlled trial of a multidomain intervention in persons aged 60+ years, with Cardiovascular Risk Factors, Aging and Dementia (CAIDE) risk score ≥ 6, no diagnosis of dementia, and below-than-expected performance in at least one of three cognitive screening tests. Randomization to a multidomain intervention (MD-Int) or regular health advice (RHA) was stratified by sex, age (>/≤ 75), and cognitive status (mild cognitive impairment (MCI)/normal cognition). MD-Int included cardiovascular risk factor control, nutritional counseling, physical activity, and cognitive training. The primary outcomes were retention rate and adherence to the intervention program. Exploratory cognitive outcomes included changes in the Neuropsychological Test Battery z-scores. Analyses were performed according to the intention to treat. RESULTS One hundred twenty-five participants were recruited (mean age: 75.64 (± 6.46); 58% women). The MD-Int (n = 61) and RHA (n = 64) groups were balanced in terms of their demographics and cognition. Fifty-two (85%) participants from the RHA group and 56 (88%) from the MD-Int group completed the study. More than 70% of the participants had high overall adherence to the intervention activities. The risk of cognitive decline was higher in the RHA group than in the MD-Int group in terms of executive function (p =.019) and processing speed scores (p =.026). CONCLUSIONS The GOIZ-ZAINDU study proved that the FINGER methodology is adaptable and feasible in a different socio-cultural environment. The exploratory efficacy results showed a lower risk of decline in executive function and processing speed in the intervention group. These results support the design of a large-scale efficacy trial. TRIAL REGISTRATION GOIZ ZAINDU feasibility trial was approved and registered by the Euskadi Drug Research Ethics Committee (ID: PI2017134) on 23 January 2018. Retrospectively registered in ClinicalTrials.gov (NCT06163716) on 8 December 2023.
Collapse
Affiliation(s)
- Mikel Tainta
- CITA-alzheimer Foundation, Donostia-San Sebastián, País Vasco, Spain
- Osakidetza, Organización Sanitaria Integrada (OSI) Goierri-Urola Garaia, País Vasco, Spain
- Instituto de Investigación Sanitaria Biodonostia, Donostia-San Sebastián, Spain
| | | | - Maria de Arriba
- CITA-alzheimer Foundation, Donostia-San Sebastián, País Vasco, Spain
| | - Myriam Barandiaran
- CITA-alzheimer Foundation, Donostia-San Sebastián, País Vasco, Spain
- Osakidetza, Organización Sanitaria Integrada (OSI) Donostialdea, País Vasco, Spain
- Instituto de Investigación Sanitaria Biodonostia, Donostia-San Sebastián, Spain
| | | | - Ane Iriondo
- CITA-alzheimer Foundation, Donostia-San Sebastián, País Vasco, Spain
| | | | - Ainara Estanga
- CITA-alzheimer Foundation, Donostia-San Sebastián, País Vasco, Spain
| | - Jon Saldias
- CITA-alzheimer Foundation, Donostia-San Sebastián, País Vasco, Spain
| | | | - Alazne Gabilondo
- Osakidetza, Organización Sanitaria Integrada (OSI) Donostialdea, País Vasco, Spain
- Osakidetza, Organización Sanitaria Integrada (OSI) Bidasoa, País Vasco, Spain
- Instituto de Investigación Sanitaria Biodonostia, Donostia-San Sebastián, Spain
| | - Naia Ros
- University of the Basque Country UPV/EHU, Donostia-San Sebastian, Spain
| | - Justo Mugica
- Osakidetza, Organización Sanitaria Integrada (OSI) Goierri-Urola Garaia, País Vasco, Spain
| | - Aitziber Barandiaran
- Osakidetza, Organización Sanitaria Integrada (OSI) Goierri-Urola Garaia, País Vasco, Spain
| | - Francesca Mangialasche
- Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
- Medical Unit Aging, Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden.
| | - Miia Kivipelto
- Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
- Medical Unit Aging, Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden
- The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
- Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland
| | - Arantzazu Arrospide
- Osakidetza, Organización Sanitaria Integrada (OSI) Debagoiena, País Vasco, Spain
- Instituto de Investigación Sanitaria Biodonostia, Donostia-San Sebastián, Spain
| | - Javier Mar
- Osakidetza, Organización Sanitaria Integrada (OSI) Debagoiena, País Vasco, Spain
- Instituto de Investigación Sanitaria Biodonostia, Donostia-San Sebastián, Spain
- Instituto de Investigación en Servicios Sanitarios Kronikgune, Barakaldo, Spain
| | | |
Collapse
|
2
|
Tainta M, Iriondo A, Ecay-Torres M, Estanga A, de Arriba M, Barandiaran M, Clerigue M, Garcia-Sebastian M, Villanua J, Izagirre A, Saldias J, Aramburu A, Taboada J, Múgica J, Barandiaran A, Arrospide A, Mar J, Martinez-Lage P. Brief cognitive tests as a decision-making tool in primary care. A population and validation study. Neurologia 2022:S2173-5808(22)00082-7. [PMID: 35963538 DOI: 10.1016/j.nrleng.2022.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2022] [Accepted: 05/24/2022] [Indexed: 11/17/2022] Open
Abstract
INTRODUCTION AND OBJECTIVES Brief cognitive tests (BCT) are used in primary care (PC) for the detection of cognitive impairment (CI). Still, there are little data on their diagnostic utility (DU) in a community setting. This work evaluates the DU at the population level of Fototest, T@M, AD8 questionnaire and MMSE. It provides new cut-off points (CoP) validated in a CI early detection program. MATERIAL AND METHODS In the population and validation samples, the evaluation was carried out in two phases, a first of screening and administration of BCT and a second of clinical diagnosis, blinded to the results of the BCT, applying the current NIA-AA criteria. The DU of BCT in the population sample was evaluated with the area under the ROC curve (aROC). Youden index and the CoP with the best specificity that ensured a sensitivity of 80% were used to decide on the most appropriate CoP. The sensitivity, specificity, and predictive values for these CoP were calculated in the validation sample. RESULTS 260 participants (23.1% with CI) from the population sample and 177 (42.4% with CI) from the validation sample were included. The Fototest has the best UD at the population level (aROC 0.851), which improves with the combination of Fototest and AD8 (aROC 0.875). The proposed CoP are AD8 ≥ 1, Fototest ≤ 35, T@M ≤ 40, and MMSE ≤ 26. CONCLUSION BCT are helpful in detecting CI in PC. This work supports the use of more demanding PoC.
Collapse
Affiliation(s)
- M Tainta
- CITA Alzheimer, Donostia-San Sebastián, Guipúzcoa, Spain; Osakidetza, Organización Sanitaria Integrada (OSI) Goierri-Urola Garaia, Spain; Instituto de Investigación Sanitaria Biodonostia, Donostia-San Sebastián, Guipúzcoa, Spain.
| | - A Iriondo
- CITA Alzheimer, Donostia-San Sebastián, Guipúzcoa, Spain
| | - M Ecay-Torres
- CITA Alzheimer, Donostia-San Sebastián, Guipúzcoa, Spain
| | - A Estanga
- CITA Alzheimer, Donostia-San Sebastián, Guipúzcoa, Spain
| | - M de Arriba
- CITA Alzheimer, Donostia-San Sebastián, Guipúzcoa, Spain
| | - M Barandiaran
- CITA Alzheimer, Donostia-San Sebastián, Guipúzcoa, Spain; Osakidetza, Organización Sanitaria Integrada (OSI) Donostialdea, Spain; Instituto de Investigación Sanitaria Biodonostia, Donostia-San Sebastián, Guipúzcoa, Spain
| | - M Clerigue
- CITA Alzheimer, Donostia-San Sebastián, Guipúzcoa, Spain
| | | | - J Villanua
- Osatek SA, Hospital Donostia, Donostia-San Sebastián, Guipúzcoa, Spain
| | - A Izagirre
- Universidad del País Vasco (UPV-EHU), Facultad de Medicina y Enfermería, Donostia-San Sebastián, Guipúzcoa, Spain
| | - J Saldias
- CITA Alzheimer, Donostia-San Sebastián, Guipúzcoa, Spain
| | - A Aramburu
- Osakidetza, Organización Sanitaria Integrada (OSI) Debabarrena, Spain
| | - J Taboada
- Osakidetza, Organización Sanitaria Integrada (OSI) Bilbao Basurto, Spain
| | - J Múgica
- Osakidetza, Organización Sanitaria Integrada (OSI) Donostialdea, Spain
| | - A Barandiaran
- Osakidetza, Organización Sanitaria Integrada (OSI) Goierri-Urola Garaia, Spain
| | - A Arrospide
- Osakidetza, Organización Sanitaria Integrada (OSI) Debagoiena, Spain; Instituto de Investigación Sanitaria Biodonostia, Donostia-San Sebastián, Guipúzcoa, Spain
| | - J Mar
- Osakidetza, Organización Sanitaria Integrada (OSI) Debagoiena, Spain; Instituto de Investigación Sanitaria Biodonostia, Donostia-San Sebastián, Guipúzcoa, Spain; Instituto de Investigación en Servicios Sanitarios Kronikgune, Barakaldo, Vizcaya, Spain
| | | |
Collapse
|
3
|
Tainta M, Iriondo A, Ecay-Torres M, Estanga A, de Arriba M, Barandiaran M, Clerigue M, Garcia-Sebastian M, Villanua J, Izagirre A, Saldias J, Aramburu A, Taboada J, Múgica J, Barandiaran A, Arrospide A, Mar J, Martinez-Lage P. Test cognitivos breves como herramienta de decisión en Atención Primaria. Estudio poblacional y de validación. Neurologia 2022. [DOI: 10.1016/j.nrl.2022.05.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
4
|
Tainta M, Ecay M, Iriondo A, Estanga A, Clerigue M, Saldias J, de Arriba M, Garcia‐Sebastian M, Aurtenetxe S, Barandiaran M, Gabilondo A, Mar J, Arrospide A, Vergara I, Mugica J, Mangialasche F, Ngandu T, Kivipelto M, Martinez‐Lage P. Adopting the FINGER multimodal intervention methodology to prevent cognitive decline in Southern Europe: The GOIZ ZAINDU pilot study. Alzheimers Dement 2021. [DOI: 10.1002/alz.056022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Mikel Tainta
- Organización Sanitaria Integrada Goierri Alto Urola Zumárraga Spain
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | - Mirian Ecay
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | - Ane Iriondo
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | | | | | - Jon Saldias
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | | | | | | | - Myriam Barandiaran
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
- Organización Sanitaria Integrada Donostialdea Donostia‐San Sebastian Spain
| | - Alazne Gabilondo
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
- Organización Sanitaria Integrada Bidasoa Irun Spain
| | - Javier Mar
- Biodonostia Health Research Institute Donostia‐San Sebastian Spain
- Gipuzkoa Primary Care – Integrated Health Care Organizations Research Unit, Alto Deba Arrasate Spain
| | - Arantzazu Arrospide
- Biodonostia Health Research Institute Donostia‐San Sebastian Spain
- Gipuzkoa Primary Care – Integrated Health Care Organizations Research Unit, Alto Deba Arrasate Spain
| | - Itziar Vergara
- Biodonostia Health Research Institute Donostia‐San Sebastian Spain
| | - Justo Mugica
- Organización Sanitaria Integrada Goierri‐Alto Urola Beasain Spain
| | | | | | | | | |
Collapse
|
5
|
Iriondo A, García-Sebastian M, Arrospide A, Arriba M, Aurtenetxe S, Barandiaran M, Clerigue M, Ecay-Torres M, Estanga A, Gabilondo A, Izagirre A, Saldias J, Tainta M, Villanua J, Blennow K, Zetterberg H, Mar J, Abad-García B, Dias IHK, Goñi FM, Martínez-Lage P. Cerebrospinal Fluid 7-Ketocholesterol Level is Associated with Amyloid-β42 and White Matter Microstructure in Cognitively Healthy Adults. J Alzheimers Dis 2021; 76:643-656. [PMID: 32538843 DOI: 10.3233/jad-200105] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
BACKGROUND Abnormal cholesterol metabolism changes the neuronal membrane and may promote amyloidogenesis. Oxysterols in cerebrospinal fluid (CSF) are related to Alzheimer's disease (AD) biomarkers in mild cognitive impairment and dementia. Cholesterol turnover is important for axonal and white matter (WM) microstructure maintenance. OBJECTIVE We aim to demonstrate that the association of oxysterols, AD biomarkers, and WM microstructure occurs early in asymptomatic individuals. METHODS We studied the association of inter-individual variability of CSF 24-hydroxycholesterol (24-OHC), 27-hydroxycholesterol (27-OHC), 7-ketocholesterol (7-KC), 7β-hydroxycholesterol (7β-OHC), amyloid-β42 (Aβ42), total-tau (t-tau), phosphorylated-tau (p-tau), neurofilament (NfL), and WM microstructure using diffusion tensor imaging, generalized linear models and moderation/mediation analyses in 153 healthy adults. RESULTS Higher 7-KC levels were related to lower Aβ42, indicative of greater AD pathology (p = 0.041) . Higher 7-KC levels were related to lower fractional anisotropy (FA) and higher mean (MD), axial (AxD), and radial (RD) diffusivity. 7-KC modulated the association between AxD and NfL in the corpus callosum splenium (B = 39.39, p = 0.017), genu (B = 68.64, p = 0.000), and fornix (B = 10.97, p = 0.000). Lower Aβ42 levels were associated to lower FA and higher MD, AxD, and RD in the fornix, corpus callosum, inferior longitudinal fasciculus, and hippocampus. The association between AxD and Aβ42 was moderated by 7K-C (p = 0.048). CONCLUSION This study adds clinical evidence to support the role of 7K-C on axonal integrity and the involvement of cholesterol metabolism in the Aβ42 generation process.
Collapse
Affiliation(s)
- Ane Iriondo
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| | - Maite García-Sebastian
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| | - Arantzazu Arrospide
- Gipuzkoa Primary Care - Integrated Health Care Organizations Research Unit, Alto Deba Integrated Health Care Organisation, Nafarroa Hiribidea, Arrasate, Gipuzkoa, Spain.,Biodonostia Health Research Institute, Paseo Doctor Begiristain, Donostia, San Sebastian, Spain
| | - Maria Arriba
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| | - Sara Aurtenetxe
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| | - Myriam Barandiaran
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| | - Montserrat Clerigue
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| | - Mirian Ecay-Torres
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| | - Ainara Estanga
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| | - Alazne Gabilondo
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| | - Andrea Izagirre
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain.,Department of Nursing II, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Spain
| | - Jon Saldias
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| | - Mikel Tainta
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| | - Jorge Villanua
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| | - Kaj Blennow
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.,Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Henrik Zetterberg
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden.,Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden.,Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.,UK Dementia Research Institute at UCL, London, United Kingdom
| | - Javier Mar
- Gipuzkoa Primary Care - Integrated Health Care Organizations Research Unit, Alto Deba Integrated Health Care Organisation, Nafarroa Hiribidea, Arrasate, Gipuzkoa, Spain.,Biodonostia Health Research Institute, Paseo Doctor Begiristain, Donostia, San Sebastian, Spain
| | - Beatriz Abad-García
- Central Analysis Service, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), Leioa, Bizkaia, Spain
| | - Irundika H K Dias
- Aston Medical Research Institute, Aston Medical School, Aston University, Birmingham, UK
| | - Felix M Goñi
- Departamento de Bioquímica, University of the Basque Country (UPV/EHU) and Instituto Biofisika (CSIC, UPV/EHU), Leioa, Bizkaia, Spain
| | - Pablo Martínez-Lage
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Gipuzkoa, Spain
| |
Collapse
|
6
|
Iriondo A, García-Sebastian M, Arrospide A, Arriba M, Aurtenetxe S, Barandiaran M, Clerigue M, Ecay-Torres M, Estanga A, Gabilondo A, Izagirre A, Saldias J, Tainta M, Villanua J, Mar J, Goñi FM, Martínez-Lage P. Plasma lipids are associated with white matter microstructural changes and axonal degeneration. Brain Imaging Behav 2021; 15:1043-1057. [PMID: 32748320 DOI: 10.1007/s11682-020-00311-9] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Dislipidemia is a risk factor for cognitive impairment. We studied the association between interindividual variability of plasma lipids and white matter (WM) microstructure, using diffusion tensor imaging (DTI) in 273 healthy adults. Special focus was placed on 7 regions of interest (ROI) which are structural components of cognitive neurocircuitry. We also investigated the effect of plasma lipids on cerebrospinal fluid (CSF) neurofilament light chain (NfL), an axonal degeneration marker. Low density lipoprotein (LDL) and triglyceride (TG) levels showed a negative association with axial diffusivity (AxD) in multiple regions. High density lipoproteins (HDL) showed a positive correlation. The association was independent of Apolipoprotein E (APOE) genotype, blood pressure or use of statins. LDL moderated the relation between NfL and AxD in the body of the corpus callosum (p = 0.041), right cingulum gyrus (p = 0.041), right fornix/stria terminalis (p = 0.025) and right superior longitudinal fasciculus (p = 0.020) and TG in the right inferior longitudinal fasciculus (p = 0.004) and left fornix/stria terminalis (p = 0.001). We conclude that plasma lipids are associated to WM microstructural changes and axonal degeneration and might represent a risk factor in the transition from healthy aging to disease.
Collapse
Affiliation(s)
- Ane Iriondo
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
| | - Maite García-Sebastian
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
| | - Arantzazu Arrospide
- Gipuzkoa Primary Care - Integrated Health Care Organizations Research Unit. Alto Deba Integrated Health Care Organisation, Arrasate, Spain.,Biodonostia Health Research Institute, Donostia-San Sebastian, Spain
| | - Maria Arriba
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
| | - Sara Aurtenetxe
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
| | - Myriam Barandiaran
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
| | - Montserrat Clerigue
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
| | - Mirian Ecay-Torres
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
| | - Ainara Estanga
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
| | - Alazne Gabilondo
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
| | - Andrea Izagirre
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain.,Department of Nursing II, Faculty of Medicine and Nursing, University of the Basque Country (UPV/EHU), Leioa, Spain
| | - Jon Saldias
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
| | - Mikel Tainta
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
| | - Jorge Villanua
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain
| | - Javier Mar
- Gipuzkoa Primary Care - Integrated Health Care Organizations Research Unit. Alto Deba Integrated Health Care Organisation, Arrasate, Spain.,Biodonostia Health Research Institute, Donostia-San Sebastian, Spain
| | - Felix M Goñi
- Departamento de Bioquímica, University of the Basque Country (UPV/EHU) and Instituto Biofisika (CSIC, UPV/EHU), Leioa, Spain
| | - Pablo Martínez-Lage
- Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, Donostia-San Sebastian, Spain.
| |
Collapse
|
7
|
Ecay M, Tainta M, Mugica J, Arriba M, Ros N, Barandiaran M, Iriondo A, Garcia‐Sebastian M, Estanga A, Aurtenetxe S, Saldias J, Clerigue M, Otaegui A, Gabilondo A, Arrospide A, Martinez‐Lage P. Cognitive results after a FINGER‐like one‐year randomized controlled multidomain intervention: The GOIZ ZAINDU pilot project. Alzheimers Dement 2020. [DOI: 10.1002/alz.042440] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Mirian Ecay
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | | | - Justo Mugica
- Organización Sanitaria Integrada Goierri‐Alto Urola Beasain Spain
| | - Maria Arriba
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | - Naia Ros
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | | | - Ane Iriondo
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | | | | | | | - Jon Saldias
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | | | - Ane Otaegui
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | | | | | | |
Collapse
|
8
|
Iriondo A, Garcia‐Sebastian M, Arrospide A, Arriba M, Aurtenetxe S, Barandiaran M, Clerigue M, Ecay M, Estanga A, Gabilondo A, Izagirre A, Saldias J, Tainta M, Villanua JA, Blennow K, Zetterberg H, Mar J, Abad‐García B, Dias I, Goñi FM, Martinez‐Lage P. CSF 7‐ketocholesterol is related to β‐amyloid and white matter microstructure in healthy adults. Alzheimers Dement 2020. [DOI: 10.1002/alz.041015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Ane Iriondo
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | | | - Arantzazu Arrospide
- Gipuzkoa Primary Care – Integrated Health Care Organizations Research Unit Alto Deba Arrasate Spain
- Biodonostia Health Research Institute San Sebastian Spain
| | - Maria Arriba
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | | | - Myriam Barandiaran
- Organización Sanitaria Integrada Donostialdea Donostia‐San Sebastian Spain
| | | | - Mirian Ecay
- Fundación CITA‐Alzheimer Fundazioa San Sebastian Spain
| | | | | | | | - Jon Saldias
- CITA Alzheimer Foundation Donostia‐San Sebastian Spain
| | | | | | - Kaj Blennow
- Institute of Neuroscience and Physiology the Sahlgrenska Academy at the University of Gothenburg Gothenburg Sweden
| | - Henrik Zetterberg
- Institute of Neuroscience and Physiology the Sahlgrenska Academy at the University of Gothenburg Gothenburg Sweden
| | - Javier Mar
- Alto Deba Hospital Arrasate‐Mondragón Spain
| | | | | | - Félix María Goñi
- University of the Basque Country (UPV/EHU) Bilbao Spain
- Instituto Biofisika (CSIC, UPV/EHU) Bilbao Spain
| | - Pablo Martinez‐Lage
- Department of Neurology Center for Research and Advanced Therapies CITA‐Alzheimer Foundation San Sebastian Spain
| |
Collapse
|
9
|
Tainta M, de Arriba M, Mugica J, Barandiaran M, Ecay M, Iriondo A, Garcia-Sebastian M, Estanga A, Aurtenetxe S, Saldias J, Clerigue M, Gabilondo A, Martinez-Lage P. P4-005: GOIZ ZAINDU: A FINGER-ADAPTED MULTIDOMAIN LIFESTYLE INTERVENTION TO PREVENT DEMENTIA IN THE BASQUE COUNTRY. Alzheimers Dement 2019. [DOI: 10.1016/j.jalz.2019.06.3664] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Mikel Tainta
- Fundación CITA-Alzhéimer Fundazioa; San Sebastian Spain
- Organización Sanitaria Integrada Goierri Alto Urola; Zumárraga Spain
| | - Maria de Arriba
- Fundación CITA-Alzheimer Fundazioa, Donostia-San; Sebastian Spain
| | - Justo Mugica
- Organización Sanitaria Integrada Goierri-Alto Urola; Beasain Spain
| | - Myriam Barandiaran
- Fundación CITA-Alzheimer Fundazioa, Donostia-San; Sebastian Spain
- Organización Sanitaria Integrada Donostialdea; Donostia-San Sebastian Spain
| | - Mirian Ecay
- Fundación CITA-Alzheimer Fundazioa; San Sebastian Spain
| | - Ane Iriondo
- Fundación CITA-Alzheimer Fundazioa, Donostia-San; Sebastian Spain
| | | | | | - Sara Aurtenetxe
- Fundación CITA-Alzheimer Fundazioa, Donostia-San; Sebastian Spain
| | - Jon Saldias
- Fundación CITA-Alzheimer Fundazioa, Donostia-San; Sebastian Spain
| | | | - Alazne Gabilondo
- Fundación CITA-Alzheimer Fundazioa, Donostia-San; Sebastian Spain
- Organización Sanitaria Integrada Bidasoa; Irun Spain
| | | | | |
Collapse
|
10
|
Wink AM, Tijms BM, Ten Kate M, Raspor E, de Munck JC, Altena E, Ecay-Torres M, Clerigue M, Estanga A, Garcia-Sebastian M, Izagirre A, Martinez-Lage Alvarez P, Villanua J, Barkhof F, Sanz-Arigita E. Functional brain network centrality is related to APOE genotype in cognitively normal elderly. Brain Behav 2018; 8:e01080. [PMID: 30136422 PMCID: PMC6160659 DOI: 10.1002/brb3.1080] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2018] [Revised: 06/20/2018] [Accepted: 06/25/2018] [Indexed: 01/19/2023] Open
Abstract
INTRODUCTION Amyloid plaque deposition in the brain is an early pathological change in Alzheimer's disease (AD), causing disrupted synaptic connections. Brain network disruptions in AD have been demonstrated with eigenvector centrality (EC), a measure that identifies central regions within networks. Carrying an apolipoprotein (APOE)-ε4 allele is a genetic risk for AD, associated with increased amyloid deposition. We studied whether APOE-ε4 carriership is associated with EC disruptions in cognitively normal individuals. METHODS A total of 261 healthy middle-aged to older adults (mean age 56.6 years) were divided into high-risk (APOE-ε4 carriers) and low-risk (noncarriers) groups. EC was computed from resting-state functional MRI data. Clusters of between-group differences were assessed with a permutation-based method. Correlations between cluster mean EC with brain volume, CSF biomarkers, and psychological test scores were assessed. RESULTS Decreased EC in the visual cortex was associated with APOE-ε4 carriership, a genetic risk factor for AD. EC differences were correlated with age, CSF amyloid levels, and scores on the trail-making and 15-object recognition tests. CONCLUSION Our findings suggest that the APOE-ε4 genotype affects brain connectivity in regions previously found to be abnormal in AD as a sign of very early disease-related pathology. These differences were too subtle in healthy elderly to use EC for single-subject prediction of APOE genotype.
Collapse
Affiliation(s)
- Alle Meije Wink
- Department of Radiology, Nuclear Medicine and PET Research, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands
| | - Betty M Tijms
- Department of Neurology, Alzheimer Centre, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands
| | - Mara Ten Kate
- Department of Neurology, Alzheimer Centre, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands
| | - Eva Raspor
- Department of Radiology, Nuclear Medicine and PET Research, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands
| | - Jan C de Munck
- Department of Physics and Medical Technology, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands
| | - Ellemarije Altena
- Université Bordeaux, Bordeaux, France.,CNRS, SANPSY, USR 3413, Bordeaux, France
| | - Mirian Ecay-Torres
- CITA Alzheimer Foundation, Donostia University Hospital, San Sebastian, Spain
| | - Montserrat Clerigue
- CITA Alzheimer Foundation, Donostia University Hospital, San Sebastian, Spain
| | - Ainara Estanga
- CITA Alzheimer Foundation, Donostia University Hospital, San Sebastian, Spain
| | | | - Andrea Izagirre
- CITA Alzheimer Foundation, Donostia University Hospital, San Sebastian, Spain
| | | | - Jorge Villanua
- CITA Alzheimer Foundation, Donostia University Hospital, San Sebastian, Spain.,Donostia Unit, Osatek, Donostia University Hospital, San Sebastian, Spain
| | - Frederik Barkhof
- Department of Radiology, Nuclear Medicine and PET Research, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.,Institutes of Neurology and Healthcare Engineering, University College London, London, UK
| | - Ernesto Sanz-Arigita
- Department of Radiology, Nuclear Medicine and PET Research, Neuroscience Campus Amsterdam, VU University Medical Centre, Amsterdam, The Netherlands.,Université Bordeaux, Bordeaux, France
| |
Collapse
|
11
|
Ecay-Torres M, Estanga A, Tainta M, Izagirre A, Garcia-Sebastian M, Villanua J, Clerigue M, Iriondo A, Urreta I, Arrospide A, Díaz-Mardomingo C, Kivipelto M, Martinez-Lage P. Increased CAIDE dementia risk, cognition, CSF biomarkers, and vascular burden in healthy adults. Neurology 2018; 91:e217-e226. [PMID: 29898969 DOI: 10.1212/wnl.0000000000005824] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2018] [Accepted: 04/11/2018] [Indexed: 12/11/2022] Open
Abstract
OBJECTIVE To investigate the cognitive profile of healthy individuals with increased Cardiovascular Risk Factors, Aging and Dementia (CAIDE) dementia risk score and to explore whether this association is related to vascular burden and CSF biomarkers of amyloidosis and neurodegeneration. METHOD Cognitively normal participants (mean age 57.6 years) from the Gipuzkoa Alzheimer Project study were classified as having high risk (HR; n = 82) or low risk (LR; n = 293) for dementia according to a CAIDE score cutoff of 9. Cognitive composites were compared between groups. We explored using generalized linear models the role of APOE genotype, MRI white matter hyperintensities (WMH), and CSF (n = 218) levels of β-amyloid1-42 (Aβ1-42), total tau (t-tau), and phosphorylated tau (p-tau) in the association between CAIDE score and cognition. RESULTS HR participants obtained lower scores on executive function (EF) (p = 0.001) and visual perception and construction (VPC) (p < 0.001) composites. EF composite was associated with CAIDE score × p-tau (p = 0.001), CAIDE score × t-tau (p = 0.001), and WMH (p = 0.003). VPC composite was associated with APOE (p = 0.001), Aβ1-42 (p = 0.004), the interaction APOE × Aβ1-42 (p = 0.003), and WMH (p = 0.004). Performance on global memory was associated with Aβ1-42 (p = 0.006), APOE (p = 0.008), and their interaction (p = 0.006). Analyses were adjusted for age, education, sex, premorbid intelligence, and stress. CONCLUSION Healthy participants at increased dementia risk based on CAIDE scores show lower performance in EF and VPC. This difference is related to APOE, WMH, and Alzheimer biomarkers.
Collapse
Affiliation(s)
- Mirian Ecay-Torres
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden
| | - Ainara Estanga
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden
| | - Mikel Tainta
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden
| | - Andrea Izagirre
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden
| | - Maite Garcia-Sebastian
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden
| | - Jorge Villanua
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden
| | - Montserrat Clerigue
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden
| | - Ane Iriondo
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden
| | - Iratxe Urreta
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden
| | - Arantzazu Arrospide
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden
| | - Carmen Díaz-Mardomingo
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden
| | - Miia Kivipelto
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden
| | - Pablo Martinez-Lage
- From the Departments of Neurology (M.E.-T., A.E., M.T., A.I., M.C., A.I., P.M.-L.) and Neuroimaging (M.G.-S., J.V.), Center for Research and Advanced Therapies, CITA-Alzheimer Foundation, San Sebastian; National University of Distance Education (M.E.-T.), Madrid; Mendaro Hospital (M.T.); Donostia Unit (J.V.), Osatek SA, Donostia University Hospital; Department of Clinical Epidemiology (I.U.), CIBER-ESP, Biodonostia Health Research Institute, San Sebastian; Gipuzkoa Primary Care-Integrated Health Care Organizations Research Unit (A.A.), Alto Deba Integrated Health Care Organisation; Health Services Research on Chronic Patients Network (A.A.), Arrasate; Donostia (A.A.), Biodonostia Health Research Institute, San Sebastian; Departamento de Psicología Básica I (C.D.-M.), Facultad de Psicología, National University of Distance Education, Madrid, Spain; and Center for Alzheimer Research (M.K.), Karolinska University Hospital, Karolinska Institutet, Huddinge, Sweden.
| |
Collapse
|
12
|
Montal V, Vilaplana E, Alcolea D, Pegueroles J, Pasternak O, González-Ortiz S, Clarimón J, Carmona-Iragui M, Illán-Gala I, Morenas-Rodríguez E, Ribosa-Nogué R, Sala I, Sánchez-Saudinós MB, García-Sebastian M, Villanúa J, Izagirre A, Estanga A, Ecay-Torres M, Iriondo A, Clerigue M, Tainta M, Pozueta A, González A, Martínez-Heras E, Llufriu S, Blesa R, Sanchez-Juan P, Martínez-Lage P, Lleó A, Fortea J. Cortical microstructural changes along the Alzheimer's disease continuum. Alzheimers Dement 2017; 14:340-351. [PMID: 29080407 DOI: 10.1016/j.jalz.2017.09.013] [Citation(s) in RCA: 90] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Revised: 09/14/2017] [Accepted: 09/20/2017] [Indexed: 01/09/2023]
Abstract
INTRODUCTION Cortical mean diffusivity (MD) and free water fraction (FW) changes are proposed biomarkers for Alzheimer's disease (AD). METHODS We included healthy control subjects (N = 254), mild cognitive impairment (N = 41), and AD dementia (N = 31) patients. Participants underwent a lumbar puncture and a 3 T magnetic resonance imaging. Healthy control subjects were classified following National Institute on Aging-Alzheimer's Association stages (stage 0, N = 220; stage 1, N = 25; and stage 2/3, N = 9). We assessed the cortical MD, cortical FW, and cortical thickness (CTh) changes along the AD continuum. RESULTS Microstructural and macrostructural changes show a biphasic trajectory. Stage 1 subjects showed increased CTh and decreased MD and FW with respect the stage 0 subjects. Stage 2/3 subjects showed decreased CTh and increased cortical MD and FW, changes that were more widespread in symptomatic stages. DISCUSSION These results support a biphasic model of changes in AD, which could affect the selection of patients for clinical trials and the use of magnetic resonance imaging as a surrogate marker of disease modification.
Collapse
Affiliation(s)
- Victor Montal
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Eduard Vilaplana
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Daniel Alcolea
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Jordi Pegueroles
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Ofer Pasternak
- Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | | | - Jordi Clarimón
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - María Carmona-Iragui
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Ignacio Illán-Gala
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Estrella Morenas-Rodríguez
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Roser Ribosa-Nogué
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Isabel Sala
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - María-Belén Sánchez-Saudinós
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Maite García-Sebastian
- Center for Research and Advanced Therapies and Memory Clinic, Fundacion CITA-Alzheimer Fundazioa, Donostia/San Sebastian, Spain
| | - Jorge Villanúa
- Center for Research and Advanced Therapies and Memory Clinic, Fundacion CITA-Alzheimer Fundazioa, Donostia/San Sebastian, Spain; Donostia Unit, Osatek SA, Donostia University Hospital, San Sebastian, Spain
| | - Andrea Izagirre
- Center for Research and Advanced Therapies and Memory Clinic, Fundacion CITA-Alzheimer Fundazioa, Donostia/San Sebastian, Spain
| | - Ainara Estanga
- Center for Research and Advanced Therapies and Memory Clinic, Fundacion CITA-Alzheimer Fundazioa, Donostia/San Sebastian, Spain
| | - Mirian Ecay-Torres
- Center for Research and Advanced Therapies and Memory Clinic, Fundacion CITA-Alzheimer Fundazioa, Donostia/San Sebastian, Spain
| | - Ane Iriondo
- Center for Research and Advanced Therapies and Memory Clinic, Fundacion CITA-Alzheimer Fundazioa, Donostia/San Sebastian, Spain
| | - Montserrat Clerigue
- Center for Research and Advanced Therapies and Memory Clinic, Fundacion CITA-Alzheimer Fundazioa, Donostia/San Sebastian, Spain
| | - Mikel Tainta
- Center for Research and Advanced Therapies and Memory Clinic, Fundacion CITA-Alzheimer Fundazioa, Donostia/San Sebastian, Spain
| | - Ana Pozueta
- Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Andrea González
- Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Eloy Martínez-Heras
- Center for Neuroimmunology, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain
| | - Sara Llufriu
- Center for Neuroimmunology, Hospital Clinic Barcelona, IDIBAPS, Barcelona, Spain
| | - Rafael Blesa
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Pascual Sanchez-Juan
- Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Pablo Martínez-Lage
- Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain; Center for Research and Advanced Therapies and Memory Clinic, Fundacion CITA-Alzheimer Fundazioa, Donostia/San Sebastian, Spain
| | - Alberto Lleó
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain
| | - Juan Fortea
- Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain.
| |
Collapse
|
13
|
Ten Kate M, Sanz-Arigita EJ, Tijms BM, Wink AM, Clerigue M, Garcia-Sebastian M, Izagirre A, Ecay-Torres M, Estanga A, Villanua J, Vrenken H, Visser PJ, Martinez-Lage P, Barkhof F. Impact of APOE-ɛ4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. Neurobiol Aging 2015; 38:14-20. [PMID: 26827639 DOI: 10.1016/j.neurobiolaging.2015.10.018] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2015] [Revised: 10/19/2015] [Accepted: 10/23/2015] [Indexed: 10/22/2022]
Abstract
The apolipoprotein E ε4 allele (APOE4) and family history of dementia (FH) are well-known risk factors for the development of sporadic Alzheimer's disease. We assessed the effects of these risk factors on gray matter (GM) volume in 295 cognitively healthy middle-aged community-dwelling subjects. Voxel-based morphometry was used to study GM volume differences between high- and low-risk subjects, based on APOE4 carriership (n = 74), first-degree FH (n = 228), or both (n = 62). No significant results were found using a corrected p value. Using a more lenient threshold (p < 0.001 and minimum cluster size of 100 voxels), APOE4 carriers had reduced GM in the striatum compared to noncarriers. Subjects with FH had reduced GM in right precuneus compared to subjects without FH. Maternal and paternal FH provided similar atrophy patterns. APOE4 carriers with FH had GM reductions in bilateral insula compared to subjects with neither APOE4 nor FH. We conclude that a family history of dementia and APOE4 carriership are both associated with regional GM decreases in cognitively healthy middle-aged subjects, with differential effects on brain regions typically affected in Alzheimer's disease.
Collapse
Affiliation(s)
- Mara Ten Kate
- Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.
| | | | - Betty M Tijms
- Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands
| | - Alle Meije Wink
- Department of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands
| | | | | | - Andrea Izagirre
- Department of Neurology, CITA-Alzheimer Foundation, San Sebastian, Spain
| | - Miriam Ecay-Torres
- Department of Neurology, CITA-Alzheimer Foundation, San Sebastian, Spain
| | - Ainara Estanga
- Department of Neurology, CITA-Alzheimer Foundation, San Sebastian, Spain
| | - Jorge Villanua
- Neuroimaging Department, CITA-Alzheimer Foundation, San Sebastian, Spain; Donostia Unit, Osatek SA, Donostia Univeristy Hospital, San Sebastian, Spain
| | - Hugo Vrenken
- Department of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands
| | - Pieter Jelle Visser
- Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands
| | | | - Frederik Barkhof
- Department of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands
| |
Collapse
|
14
|
Tijms BM, Kate MT, Wink AM, Visser PJ, Ecay M, Clerigue M, Estanga A, Garcia Sebastian M, Izagirre A, Villanua J, Martinez Lage P, van der Flier WM, Scheltens P, Sanz Arigita E, Barkhof F. Gray matter network disruptions and amyloid beta in cognitively normal adults. Neurobiol Aging 2015; 37:154-160. [PMID: 26559882 DOI: 10.1016/j.neurobiolaging.2015.10.015] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2015] [Revised: 09/28/2015] [Accepted: 10/16/2015] [Indexed: 12/11/2022]
Abstract
Gray matter networks are disrupted in Alzheimer's disease (AD). It is unclear when these disruptions start during the development of AD. Amyloid beta 1-42 (Aβ42) is among the earliest changes in AD. We studied, in cognitively healthy adults, the relationship between Aβ42 levels in cerebrospinal fluid (CSF) and single-subject cortical gray matter network measures. Single-subject gray matter networks were extracted from structural magnetic resonance imaging scans in a sample of cognitively healthy adults (N = 185; age range 39-79, mini-mental state examination >25, N = 12 showed abnormal Aβ42 < 550 pg/mL). Degree, clustering coefficient, and path length were computed at whole brain level and for 90 anatomical areas. Associations between continuous Aβ42 CSF levels and single-subject cortical gray matter network measures were tested. Smoothing splines were used to determine whether a linear or nonlinear relationship gave a better fit to the data. Lower Aβ42 CSF levels were linearly associated at whole brain level with lower connectivity density, and nonlinearly with lower clustering values and higher path length values, which is indicative of a less-efficient network organization. These relationships were specific to medial temporal areas, precuneus, and the middle frontal gyrus (all p < 0.05). These results suggest that mostly within the normal spectrum of amyloid, lower Aβ42 levels can be related to gray matter networks disruptions.
Collapse
Affiliation(s)
- Betty M Tijms
- Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands.
| | - Mara Ten Kate
- Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands
| | - Alle Meije Wink
- Department of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands
| | - Pieter Jelle Visser
- Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands; Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands
| | - Mirian Ecay
- Department of Neurology, CITA-Alzheimer Foundation, San Sebastian, Spain
| | | | - Ainara Estanga
- Department of Neurology, CITA-Alzheimer Foundation, San Sebastian, Spain
| | | | - Andrea Izagirre
- Department of Neurology, CITA-Alzheimer Foundation, San Sebastian, Spain
| | - Jorge Villanua
- Department of Neurology, CITA-Alzheimer Foundation, San Sebastian, Spain; Donostia Unit, Osatek SA, Donostia University Hospital, San Sebastian, Spain
| | | | - Wiesje M van der Flier
- Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands; Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands
| | - Philip Scheltens
- Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands
| | | | - Frederik Barkhof
- Department of Radiology and Nuclear Medicine, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, the Netherlands
| |
Collapse
|
15
|
Tijms BM, Kate M, Wink AM, Visser PJ, Ecay M, Estanga A, Clerigue M, Garcia-Sebastian M, Izagirre A, Villanua J, Martinez-Lage P, Flier WM, Scheltens P, Sanz-Arigita E, Barkhof F. P3‐158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.1529] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
| | - Maraten Kate
- VU University Medical CenterAmsterdamNetherlands
| | | | - Pieter Jelle Visser
- Alzheimer Center Limburg, School for Mental Health and NeuroscienceMaastricht UniversityMaastrichtNetherlands
- Alzheimer CenterVU University Medical CenterAmsterdamNetherlands
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Kate M, Sanz-Arigita E, Tijms BM, Wink AM, Clerigue M, Garcia-Sebastian M, Izagirre A, Ecay M, Estanga A, Villanua JA, Vrenken H, Visser PJ, Martinez-Lage P, Barkhof F. IC‐P‐108: Impact of ApoE‐Ɛ4 and family history of dementia on gray matter atrophy in cognitively healthy middle‐aged adults. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.06.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Mara Kate
- VU University Medical CenterAmsterdamNetherlands
| | | | | | | | | | | | | | | | | | | | - Hugo Vrenken
- VU University Medical CenterAmsterdamNetherlands
| | | | | | | |
Collapse
|
17
|
Kate M, Sanz-Arigita E, Tijms BM, Wink AM, Clerigue M, Garcia-Sebastian M, Izagirre A, Ecay M, Estanga A, Villanua JA, Vrenken H, Visser PJ, Martinez-Lage P, Barkhof F. O2‐09‐01: Impact of ApoE‐ɛ4 and family history of dementia on gray matter atrophy in cognitively healthy middle‐aged adults. Alzheimers Dement 2015. [DOI: 10.1016/j.jalz.2015.07.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Affiliation(s)
- Mara Kate
- VU University Medical CenterAmsterdamNetherlands
| | | | | | | | | | | | | | | | | | | | - Hugo Vrenken
- VU University Medical CenterAmsterdamNetherlands
| | | | | | | |
Collapse
|
18
|
Barnadas A, Mendiola C, Casado A, Villar A, Jimeno J, Clerigue M, Rosell R, Diaz-Rubio E, Cortés-Funes H, García de Paredes M. Combination of oral idarubicin and prednimustine in advanced breast cancer: a phase II study. Eur J Cancer 1997; 33:312-5. [PMID: 9135508 DOI: 10.1016/s0959-8049(96)00372-3] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The aim of this study was to assess the efficacy and toxicity of an idarubicin-prednimustine combination in advanced breast cancer. 19 patients received idarubicin 35 mg/m2 day 1 and prednimustine 100 mg/m2 days 2-6, every 21 days. Three objective responses with a median duration of 7 months were observed. Tolerance was good. A further 23 patients were given idarubicin administered at 15 mg/m2 days 1, 2 and 3 and prednimustine at the aforementioned dosage. 8 (35%) showed an objective response (4 CRs, 4 PRs) with a median duration of 6 months. No severe toxicity was observed. Results suggest activity of idarubicin-prednimustine combinations in advanced breast cancer, and further studies are indicated since this regimen is easily administered, especially to elderly patients.
Collapse
Affiliation(s)
- A Barnadas
- Department of Medical Oncology, Hospital Germans Trias y Pujol, Badalona, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Abstract
Lymphokine-activated killer (LAK) cells from human peripheral blood mononuclear cells cultured with recombinant interleukin-2 (IL-2) have been used clinically in adoptive immunotherapy for cancer patients. To study the influence of LAK cells and IL-2 on haematopoiesis, an in vitro assay system for colony formation of granulocyte-macrophage progenitor cells (GM-CFC) was used. LAK cells from cultures of either human peripheral blood (PB) or human bone marrow (BM) mononuclear cells were both inhibitory to allogeneic BM-derived GM-CFC. Inhibitory activity could be transferred with supernatants from co-cultures of LAK cells and BM targets, but also from the IL-2 activated PB- or BM-derived cells alone. The inhibitory activity from the initially non-cytotoxic/non-inhibitory BM population was rapidly induced by IL-2 activation, and preceded the generation of cytotoxic LAK cells in the culture. These experiments show that inhibition of haematopoietic progenitor cells by IL-2 is not dependent on generation of cytotoxic LAK cells, but rather the result of IL-2-induced cytokine production. We conclude that the synergistic action of interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) may contribute to inhibition, but that also other cytokines are responsible for the observed inhibition of BM-derived GM-CFC.
Collapse
Affiliation(s)
- M Clerigue
- Department of Immunology, Karolinska Institute, Stockholm, Sweden
| | | | | | | |
Collapse
|